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ABSTRACT Virus-speciﬁc CD8 T cell response seems to play a signiﬁcant role in the
outcome of hepatitis delta virus (HDV) infection. However, the HDV-speciﬁc T cell
epitope repertoire and mechanisms of CD8 T cell failure in HDV infection have been
poorly characterized. We therefore aimed to characterize HDV-speciﬁc CD8 T cell
epitopes and the impacts of viral mutations on immune escape. In this study, we
predicted peptide epitopes binding the most frequent human leukocyte antigen
(HLA) types and assessed their HLA binding capacities. These epitopes were charac-
terized in HDV-infected patients by intracellular gamma interferon (IFN-) staining.
Sequence analysis of large hepatitis delta antigen (L-HDAg) and HLA typing were
performed in 104 patients. The impacts of substitutions within epitopes on the CD8
T cell response were evaluated experimentally and by in silico studies. We identiﬁed
two HLA-B*27-restricted CD8 T cell epitopes within L-HDAg. These novel epitopes
are located in a relatively conserved region of L-HDAg. However, we detected mo-
lecular footprints within the epitopes in HLA-B*27-positive patients with chronic HDV
infections. The variant peptides were not cross-recognized in HLA-B*27-positive pa-
tients with resolved HDV infections, indicating that the substitutions represent viral
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escape mutations. Molecular modeling of HLA-B*27 complexes with the L-HDAg
epitope and its potential viral escape mutations indicated that the structural and
electrostatic properties of the bound peptides differ considerably at the T cell recep-
tor interface, which provides a possible molecular explanation for the escape mecha-
nism. This viral escape from the HLA-B*27-restricted CD8 T cell response correlates
with a chronic outcome of hepatitis D infection. T cell failure resulting from immune
escape may contribute to the high chronicity rate in HDV infection.
IMPORTANCE Hepatitis delta virus (HDV) causes severe chronic hepatitis, which af-
fects 20 million people worldwide. Only a small number of patients are able to clear
the virus, possibly mediated by a virus-speciﬁc T cell response. Here, we performed a
systematic screen to deﬁne CD8 epitopes and investigated the role of CD8 T cells in
the outcome of hepatitis delta and how they fail to eliminate HDV. Overall the num-
ber of epitopes identiﬁed was very low compared to other hepatotropic viruses. We
identiﬁed, two HLA-B*27-restricted epitopes in patients with resolved infections. In
HLA-B*27-positive patients with chronic HDV infections, however, we detected es-
cape mutations within these identiﬁed epitopes that could lead to viral evasion of
immune responses. These ﬁndings support evidence showing that HLA-B*27 is im-
portant for virus-speciﬁc CD8 T cell responses, similar to other viral infections. These
results have implications for the clinical prognosis of HDV infection and for vaccine
development.
KEYWORDS cytotoxic T lymphocyte, epitope mapping, immune escape, immune
selection, large hepatitis delta antigen
It is estimated that 15 to 20 million patients worldwide carry hepatitis delta virus(HDV), a virus that causes the most severe form of viral hepatitis, including fulminant
hepatitis, and a high rate of cirrhosis (1, 2). The HDV virion is composed of a circular
single-stranded RNA consisting of around 1,700 bases and depends on hepatitis B virus
(HBV) for progeny virus production and spread. The antigenomic open reading frame
(ORF) of HDV encodes the only viral protein, hepatitis delta antigen (HDAg), in two
forms, small and large hepatitis delta antigen (S- and L-HDAg). L-HDAg contains the
protein sequence of S-HDAg but has an additional 19 amino acids (aa) at the C terminus
(3, 4).
Two courses of HDV infection are known (5). HDV and HBV coinfection of patients
shows a course similar to that of acute HBV monoinfection, and the majority of patients
clear both HBV and HDV. HDV superinfection in chronic HBV infection, in contrast,
results in a high rate of HDV persistence. Antibodies recognizing both HDV proteins are
detected at low titers during acute infection and reach high levels during chronic
infection, but they are not able to neutralize the virus (6). The efﬁcacy of current
therapies against HDV, e.g., with PEGylated interferon, is very limited (7).
Liver damage after superinfection of HBV carriers with HDV results in transaminase
elevation. This observation, as well as the fact that HDV itself is not cytopathic (8), may
indicate that cytotoxic T lymphocytes (CTL) are involved in the destruction of hepato-
cytes. T cell responses against HDV antigens seem to be weak, but very little is known
about T cell responses controlling HDV infection, and T cell epitopes are poorly character-
ized. Initial studies in animal models have shown that a CD8 T cell response against S- and
L-HDAgs can be generated. In mice, we demonstrated that immunization with a
plasmid DNA vaccine expressing HDAg primed a functional CD4 and CD8 T cell immune
response against both forms of delta antigens (9). These T cells prevented the devel-
opment of L-HDAg-expressing tumors in 80 to 100% of immunized mice (9). Moreover,
a DNA prime and adenoviral vector boost vaccination with L-HDAg protected wood-
chucks from HDV in the setting of simultaneous infection with woodchuck hepatitis
virus (WHV) and HDV (10). Nisini et al. demonstrated a polyspeciﬁc but weak CD4 T cell
response to HDAg in patients that was related to the resolution of HDV-induced disease
activity (11). CD8 T cell responses to two human leukocyte antigen (HLA)-A*02:01-
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restricted HDAg epitopes have been described in patients with resolved HDV infection
that were absent in patients with an actively replicating chronic infection (12).
In recent years, much has been learned about how human viruses establish chronic
and long-lasting infections by escaping the T cell immune response. For the clinically
most relevant chronic viral infections, i.e., with HIV, HBV, and hepatitis C virus (HCV), it
has been demonstrated that, despite differences in the natural course of infection in
humans, failure of T cell responses is a typical phenomenon (13–15). Viral immune
escape variants may contribute to the failure of T cell responses and allow viral
persistence and high-level replication. CD8 T cell responses are restricted by host HLA
class I molecules, with enormous allelic variation between individuals and across
different populations. Since the repertoire of the CD8 T cell response is dictated by the
genetic HLA background of the individual host, diverse peptide epitopes derived from
viral proteins maybe presented.
CD8 T cells have been shown to elicit signiﬁcant selection pressure in chronic viral
infection. In HBV (14), HCV (16), and HIV (17, 18) infections, selection of viral escape
variants has been reported. For HDV, a previous study suggested evidence for positive
selection within the predicted HDV epitopes restricted by HLA-A*02:01 (19); however,
no in vitro experiments have been carried out conﬁrming that immune escape func-
tionally impairs the virus-speciﬁc T cell response. The aims of this study, therefore, were
(i) to characterize the variability of the only HDV protein, L-HDAg, in a large cohort of
patients; (ii) to identify HDAg-speciﬁc CD8 T cell epitopes for frequent HLA alleles by in
silico and in vitro analyses; and (iii) to evaluate whether immune escape of HDV from
CD8 T cell responses by mutation of relevant CD8 epitopes contributes to the persis-
tence of HDV after superinfection of HBV carriers.
RESULTS
HDV epitope prediction and MHC binding capabilities of predicted epitopes in
vitro. Two hundred HDV genotype 1 sequences of L-HDAg, retrieved from GenBank,
were submitted for epitope prediction using two different online tools for the predic-
tion of major histocompatibility complex (MHC) class I binding epitopes (implemented
in the Immune Epitope Database [IEDB] and the SYFPEITHI database). This prediction of
L-HDAg was done for frequent MHC class I alleles in the European population (20), as
well as HLA-B*27, which, despite its low frequency, has been shown to play a protective
role against a number of serious human viral infections, such as HCV and HIV (21–23).
Two predicted HLA-B*27-restricted epitopes, i.e., L-HDAg99–108 (RRDHRRRKAL) and
L-HDAg103–112 (RRRKALENKK), showed the best percentile scores (Table 1). Although for
most of the common HLA alleles no peptides reached average prediction scores that
were comparable to those of the peptide epitopes known from other viruses, we
selected 15 peptides with the best predicted binding scores to HLA-A*01, -A*02, -A*03,
and -A*24 and HLA-B*07 and -B*27 to determine their binding afﬁnities experimentally.
HLA binding was assessed by UV-induced peptide exchange and compared to that
of a known high-afﬁnity ligand of the respective HLA class I molecules. None of the
synthesized peptides predicted to bind to HLA-A*01, -A*02, -A*03, -A*24, or -B*07
bound with an afﬁnity of 25% compared to the respective positive control (Fig. 1).
Only the two peptide ligands for HLA-B*27, aa 99 to 108 (RRDHRRRKAL) and 103 to 112
(RRRKALENKK), showed high binding afﬁnities of 120 and 111.7%, respectively, relative
to that of KRWIILGLNK, a well-known HLA-B*27-restricted HIV epitope, which was used
as positive control.
Detection of HDV-speciﬁc CD8 T cells in patients with resolved HDV infections.
To determine if the predicted peptide epitopes would be recognized in HDV infection,
in a ﬁrst set of experiments, we analyzed peripheral blood mononuclear cells (PBMCs)
of one HLA-B*27-positive and three HLA-B*27-negative patients who had resolved HDV
infections. Using an overlapping peptide library spanning the whole L-HDAg (Table 2)
and divided into 8 peptide pools (A to H), we detected a T cell response only in the
HLA-B*27-positive patient A (Fig. 2). The CD8 T cell response, shown by intracellular
cytokine staining (ICS), was induced by peptides of pool D (0.53% gamma interferon-
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positive [IFN-] CD8 T cells compared to 0.04% relative to negative-control pep-
tides). Restimulation of the cells with the single peptides of pool D showed that the
response was present only after stimulation with peptide D14. This 16-mer peptide
(L-HDAg98–113 [ERRDHRRRKALENKKK]) includes the sequences of two HLA-B*27:05
peptide ligands, L-HDAg99–108 (RRDHRRRKAL) and L-HDAg103–112 (RRRKALENKK), both
of which we had predicted and proven to bind to this allele (Table 1 and Fig. 1). Four
HLA-B*27-negative patients with resolved HDV infections and ﬁve HLA-B*27-positive
patients with chronic HDV infections (HDV RNA positive), as well as two HLA-B*27-
positive individuals without HBV, HCV, or HDV infection (anti-HDV and HDV RNA
negative) used as controls, showed no response to the 16-mer or to the single peptide
epitopes (Fig. 3).
To conﬁrm the CD8 T cell response observed in patient A, we were able to gain
access to two additional HLA-B*27-positive individuals (patients B and C) with resolved
HDV infections (Fig. 2B and C), while PBMCs from patient A were no longer available.
Stimulation of PBMCs from both patients B and C with the 16-mer peptide (aa 98 to 113
[ERRDHRRRKALENKKK]) resulted in an IFN- response similar to what had been the case
with patient A. Interestingly, patient B recognized the HLA-B*27:05 ligand L-HDAg99–108
(RRDHRRRKAL) (Fig. 2B) and patient C recognized L-HDAg103–112 (RRRKALENKK) (Fig.
2C), indicating a differential CD8 T cell response in HLA-B*27-positive individuals. Our
HLA-B*27 patients were recruited from Germany, Italy, and Spain, where the HLA-B*27
subtypes (alleles) B*27:05 and B*27:02 are prevalent. Since these two HLA-B*27 sub-
types may inﬂuence the targeting of virus-speciﬁc CD8 T cell epitopes (24), we
analyzed the presentation of the epitope L-HDAg103–112 by HLA-B*27:05 and -B*27:02.
Of note, the epitope was presented by both HLA-B*27 subtypes (Fig. 4).
According to prediction and binding assays, in our hands, the two previously
described HLA-A*02-restricted peptides (L-HDAg26–34 and L-HDAg43–51) (12) had low
prediction scores and no capacities for binding to the HLA-A*02 molecule in vitro.
Nevertheless, we intended to conﬁrm the two epitopes in 4 HLA-A*02-positive patients
with resolved HDV infections. We observed no speciﬁc T cell response in PBMCs of all
4 patients after 10 days of culture (Fig. 5).
Molecular footprints for viral immune escape in HLA-B*27 epitopes L-HDAg99–108
and L-HDAg103–112. Several studies have demonstrated that viral mutations leading to
sequence variation within T cell epitopes are selected as a result of immune pressure.
TABLE 1 Best predicted epitopes on L-HDAg for the selected HLA allelesa
HLA Position (aa) Sequence Length
Score
IEDB SYFPEITHI
A*01 75–83 RTDQMEVDS 9 3.2 17
94–102 FTDKERQHD 9 1.3 17
A*02 43–51 KLEEDNPWL 9 1.3 23
143–152 RVAGPPVGGV 10 4.2 23
198–206 ILFPSDPPF 9 0.8 16
A*03 53–61 NIKGILGKK 9 2.7 22
89–97 PLRGGFTDK 9 2.1 28
A*24 49–57 PWLGNIKGI 9 3.9 13
192–200 RGFPWDILF 9 1.1 13
198–206 ILFPSDPPF 9 2.4 11
B*07 68–76 APPAKRART 9 1.9 21
71–79 AKRARTDQM 9 3.1 12
168–176 VPSMQGVPE 9 3.0 16
B*27 99–108 RRDHRRRKAL 10 0.35 24
103–112 RRRKALENKK 10 0.20 29
aThe predicted epitopes were determined for HLA-A*01, A*02, A*03, A*24, B*07, and B*27 using two different
algorithms (IEDB [recommended] and SYFPEITHI), which were described in detail previously (39, 57).
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These mutations can result in failure of T cell recognition and may be responsible for
viral persistence. We therefore compared the coding sequences for L-HDAg by direct
sequencing in a cohort of 104 patients with chronic HDV infection who were HLA
typed. Sequence alignment and subsequent phylogenetic analysis indicated that all the
isolates were HDV genotype 1 (data not shown). Within the 214-aa L-HDAg, we
observed high variability, e.g., at amino acid positions 9, 121, and 191, whereas aa 10,
99, and 115 were conserved in all the isolates (data not shown). These analyses
indicated that the candidate HLA-B*27-restricted epitopes (aa 99 to 108 and 103 to 112)
are located in a relatively conserved region of L-HDAg.
Comparing HLA-B*27-positive and -negative patients, we found a higher rate of
substitutions within the veriﬁed HLA-B*27 epitopes L-HDAg99–108 and L-HDAg103–112 in
HDV isolates from the six HLA-B*27-positive individuals (Fig. 6). Sequence analysis
indicated that two amino acid substitutions, R105K and K106M, were signiﬁcantly
enriched in isolates from HLA-B*27-positive patients (P  0.002). Two additional
residues within this region, L-HDAg aa 100 and 112, showed some variations in both
HLA-B*27-positive and -negative patients that were present not only in genotype 1, but
also in all 8 genotypes of HDV following comprehensive analysis of 621 available
isolates from GenBank (Fig. 7). We also analyzed amino acid sequences upstream of
FIG 1 MHC binding assay of the highest-ranking predicted L-HDAg epitopes. Binding to the indicated HLA
molecules was assessed by UV-induced ligand exchange. A total of 15 different predicted epitopes were tested for
binding HLA-A*01:01 (n  2), HLA-A*02:01 (n  3), HLA-A*03:01 (n  2), HLA-A*24:02 (n  3), HLA-B*07:02 (n 
3), and HLA-B*27:05 (n  2). L-HDAg198–206 was tested with HLA-A*2:01 and -A*24:02. Binding of predicted peptide
epitopes is shown as percent binding of the indicated epitopes with high binding afﬁnities for the respective HLA
molecules. Means and standard deviations (SD) are shown. Negative controls (Neg. Cont.) included exchange of a
nonbinder and UV illumination in the absence of any peptide.
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L-HDAg99–108 and downstream of L-HDAg103–112 in isolates from HLA-B*27-positive
versus HLA-B*27-negative patients with chronic HDV infections. These analyses indi-
cated no enrichment of mutations in the ﬂanking regions of these two epitopes, as
described previously (25). The L-HDAg sequence analysis was also extended to another
13 predicted epitopes restricted by HLA-A*01, -A*02, -A*03, -A*24, or -B*07 (Table 1).
Importantly, for none of these candidate epitopes was a higher frequency of viral
mutations observed in isolates from patients positive for the respective HLA type
compared to patients negative for the alleles. These results are consistent with those of
prediction and binding assays.
Notably, two of the three HLA-B*27-positve patients (Fig. 6, no. 2 and 6) with
wild-type epitopes had resolved the HDV infection in follow-up after more than 3 years
of persistent infection.
To identify additional minor variants, next-generation sequencing was performed in
HDV isolates from the HLA-B*27-positive patients and the six randomly selected
HLA-B*27-negative patients. The analyses of 43,724 validated sequences demonstrated
that the substitutions identiﬁed by direct sequencing were present in 100% of the
haplotype 4/5 HLA-B*27-positive patients but in 0/6 HLA-B*27-negative patients. Ad-
ditional low-frequency substitutions (0.3 to 0.8% of the sequences) in the L-HDAg
epitope coding region were observed only in HLA-B*27-positive cases (Table 3). Hap-
lotypes at position 112 showed a polymorphism, K/R, that was observed in both
HLA-B*27-positive and -negative cases (Fig. 6). In two HLA-B*27-negative cases, a
mixture of 112K and R was observed in minor proportions (Table 3). Thus, distinct
molecular footprints were identiﬁed in the L-HDAg coding sequences of HDV isolates
in HLA-B*27-positive patients.
Impacts of footprints within HLA-B*27 epitopes L-HDAg99–108 and L-HDAg103–112
on the CD8 T cell response. To investigate whether the amino acid variations detected
TABLE 2 Library of HDV peptidesa
Pool Peptide name Position (aa) Sequence
A A1 1–16 MSRSESRKNRGGREEL
A A2 2–17 SRSESRKNRGGREELL
A A3 10–23 RGGREELLEQWVAGRK
A A4 18–33 EQWVAGRKKLEELERD
B B5 26–41 KLEELERDLRKTKKKL
B B6 34–49 LRKTKKKLKKIEDENP
B B7 42–57 KKIEDENPWLGNIKGI
B B8 50–65 WLGNIKGILGKKDKDG
C C9 58–73 LGKKDKDGEGAPPAKR
C C10 66–81 EGAPPAKRARTDQMEV
C C10a 66–81 EGAPPAKRARTDRMEV
C C11 74–89 ARTDQMEVDSGPGKRP
D D11a 74–89 ARTDRMEVDSGPGKRP
D D12 82–97 DSGPGKRPLRGGFTDK
D D13 90–105 LRGGFTDKERRDHRRR
D D14 98–113 ERRDHRRRKALENKKK
E E15 106–121 KALVNKKKQLSAGGKN
E E16 114–129 QLSAGGKNLSKEEEEE
E E17 122–137 LSKEEEEELRRLTEED
E E18 130–145 LRRLTEEDERRERRVA
F F19 138–153 ERRERRVAGPPVGGVN
F F20 146–161 GPPVGGVNPLEGGSRG
F F21 154–169 PLEGGSRGAPGGGFVP
F F22 162–177 APGGGFVPNLQGVPES
G G23 170–185 NLQGVPESPFSRTGEG
G G23a 170–185 NLQGVPESPFARTGEG
G G24 178–193 PFSRTGEGLDIRGNQG
G G24a 178–193 PFARTGEGLDIRGNQG
H H25 186–201 LDIRGNQGFPQDTLFP
H H26 194–209 FPQDTLFPADPPLSPQ
H H27 199–214 LFPADPPLSPQSCRPQ
aOverlapping 16-mer peptides spanning the whole HDAg open reading frame of 214 amino acids that were
used for T cell stimulation.
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FIG 2 Peptide recognition by T cells from patients with resolved HDV infections. PBMCs were stimulated with the indicated peptides
after in vitro expansion and surface staining for T cell markers. ICS was performed and analyzed by ﬂow cytometry. (A) CD8 and IFN-
staining after stimulation with pools A to H of overlapping 16-mer peptides spanning the whole L-HDAg and the indicated single
(Continued on next page)
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in our patient cohort had an impact on the T cell response, we tested the variant
peptides for cross-recognition in the HLA-B*27 patients with resolved HDV infections
(Fig. 8). Further characterization of L-HDAg103–112 using PBMCs from patient C indicated
equal recognition of the 10-mer epitope and the corresponding 9-mer (L-HDAg104–112
[RRKALENKK]) (Fig. 8A). Variation at position 112 (K112R), observed in both HLA-B*27-
positive and -negative patient groups, did not inﬂuence CD8 T cell responses. There-
fore, we investigated the impacts of R105K and K106M substitutions in both 10-mer
and 9-mer epitopes with lysine (K) at position 112. While R105K substitutions affected
the corresponding T cell response in none of the epitopes, the K106M substitution
completely impaired the speciﬁc T cell response to 10-mer and 9-mer epitopes.
Equivalent results were obtained when an IFN- enzyme-linked immunosorbent spot
(ELISpot) assay instead of intracellular cytokine staining was performed as a readout
(Fig. 9). This indicated that for patients recognizing the epitope L-HDAg103–112, only the
variation K106M is able to allow HDV to escape virus-speciﬁc immunity.
In addition to the variations R105K and K106M within the L-HDAg99–108 epitope, we
also observed variations at position 100 (boldface), the second amino acid in that
epitope, throughout all the studied isolates (RRDHRRRKAL, RQDHRRRKAL, REDHRRR
KAL, and RKDHRRRKAL) (Fig. 6). To address the impacts of these amino acid substitu-
tions on T cell recognition, we tested the peptide variants in HLA-B*27-positive patient
B, with resolved HDV infection, for cross-recognition (Fig. 8B). This assay conﬁrmed that
L-HDAg99–108 induced CD8 T cell responses irrespective of aa 100 variations (R[R/Q/E
/K]DHRRRKAL) (Fig. 8B, left). However, IFN- production was not observed when PBMCs
were stimulated with peptide variants either at position 105 (R105K) or at position 106
(K106M) (Fig. 8B, right). This matched our ﬁnding that amino acid substitutions R105K
and K106M were observed exclusively in HLA-B*27-positive patients with chronic HDV
infections, whereas substitutions at position 100 were observed in patients with diverse
HLA haplotypes (Fig. 6) and are also prevalent in other HDV genotypes (Fig. 7). Taken
together, our data provide strong evidence that two residues, 105 and 106, within the novel
HLA-B*27-restricted CD8 T cell epitope L-HDAg99–108 are selected under immune pressure
by the CD8 T cell response and that the variants confer an immune escape on HDV.
In silico structural analysis of six representative peptide variants bound to
HLA-B*27:05. To gain a detailed molecular understanding of the HLA-B*27:05 binding
mode of the newly identiﬁed epitopes and their T cell activation properties, we
performed a molecular dynamics (MD)-based analysis of the binding properties of six
representative peptides bound to HLA-B*27:05: the epitope L-HDAg99–108 (RRDHRRRK
AL), the naturally occurring L-HDAg peptide variants mutated at amino acid position
100 (Q/E/K100), and the immune escape variants R105K and K106M (Table 4 and Fig. 10
to 12).
In Table 4, the experimental binding and T cell activation data for these peptides are
provided, together with the calculated interaction energies. The experimental MHC
binding data suggest that R100 is the strongest binder among all the peptides varying
at position 100 (Table 4, column 3). This is also reﬂected in the calculated interaction
energies for the Q100 and E100 variants (Table 4, column 5), but not for K100. Thus, two
further analyses of the theoretical results were performed. First, a visual analysis of the
structural binding properties was performed (Fig. 10 and 12), which showed that all the
variants (Q/E/K100) ﬁt less well into the binding site than R100. Second, a quantitative
analysis of the hydrogen bond network between the peptides and the HLA-B*27:05
binding site (data not shown) was done, which substantiated the visual observations.
The area of the HLA-B*27:05 binding site in which residue 100 is located consists of a
very deep pocket with two hydrogen bond acceptors/donors, E69 and T48, at its
FIG 2 Legend (Continued)
peptides from pool D. Peptide D14 was L-HDAg98–113 (ERRDHRRRKALENKKK). (B and C) Representative dot plots of CD8 T cell responses
of patient B (B) and patient C (C) to the 16-mer peptide D14, as well as the two indicated 10-mer candidate epitopes L-HDAg99–108
(RRDHRRRKAL) and L-HDAg103–112 (RRRKALENKK) within the 16-mer peptide. Negative controls were treated exactly the same as the
other samples from the respective patients but were not stimulated with peptide prior to intracellular IFN- staining.
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FIG 3 HLA-B*27-restricted epitope recognition by HLA-B*27-negative patients with resolved infections,
HLA-B*27-positive patients with chronic HDV infections, and HLA-B*27- positive healthy individuals. (A)
PBMCs from four HLA-B*27-negative patients with resolved HDV infections (rHDV) were stimulated with the
(Continued on next page)
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bottom (Fig. 10A, inset). This pocket is optimally ﬁlled by the large R residue, which
forms three or four stable hydrogen bonds with E69 and T48, while K, containing only
one charged group, interacts alternatively with E69 or T48, with its side chain ﬂipping
back and forth between the two residues during the simulation, indicating unstable
binding. Q and E are simply too small to form stable interactions within the pocket, as
their side chains cannot reach the bottom of the binding site. Therefore, our compu-
tational analyses can provide an explanation for the experimentally observed strong
binding of the R100 wild type and are consistent with the experimental HLA-B*27:05
binding data.
To estimate the inﬂuence of the R105K and K106M mutations on the T cell response,
we investigated their effects on the shape and electrostatic potential of the solvent-
exposed surface region of the peptides, as this is the region to which the T cell receptor
(TCR) binds (Fig. 10 and 12). In addition, the same visual analysis and quantitative
hydrogen bond analysis as for the R100 variants were performed (Fig. 10 and 11). For
the L-HDAg99–108 epitope (Fig. 10C), the TCR interface is dominated by R105 and R104,
forming a very characteristic steric and electrostatic ﬁngerprint, which seems to be
important for TCR recognition, as for both variants, which do not show any T cell
response, large differences were observed in the TCR interaction region (Fig. 10D and
H). The R105K mutation leads directly to strong changes in the electrostatic potential
of the peptide in the TCR interaction area (Fig. 10D). In the K106M variant, the effects
are more complex and are caused indirectly by a different hydrogen bond pattern
within the peptide, which leads to considerable changes in the conformation and thus
FIG 3 Legend (Continued)
pool of peptides, including the 16-mer peptide (D14) spanning both identiﬁed HLA-B*27-restricted epitopes,
and evaluated for IFN- production by CD8 T cells. (B) PBMCs from ﬁve HLA-B*27-positive patients with
chronic HDV infections (cHDV) were expanded with a 16-mer peptide spanning both HLA-B*27-restricted
epitopes, as well as single 10-mer epitopes (cHDV-1 to -3) or only 10-mers (cHDV-4 and -5). IFN- production
was evaluated by surface and intracellular staining after stimulation. (C) The same experiment as in panel B
was performed on PBMC samples from 2 HLA-B*27-positive individuals without HBV, HCV, or HDV infection
(Healthy-1 and -2). Negative controls (Neg. Ctrl.) were treated exactly like the other samples from the
respective patients but were not stimulated with peptide prior to intracellular IFN- staining. Positive
controls (Pos. Ctrl.) were stimulated with phorbol myristate acetate (PMA)/ionomycin prior to intracellular
IFN- staining.
FIG 4 The epitope HLA-B*27 L-HDAg103–112 is restricted by HLA-B*27 subtypes HLA-B*27:05 (HLA-B*27 prototype) and HLA-B*27:02 (minor Mediterranean
HLA-B*27 subtype). PBMCs were expanded in the presence of peptide RRRKALENKK for 10 days. Then, intracellular IFN- staining was performed after direct
stimulation with peptide (left) or stimulation with EBV-immortalized B cell lines (BCL) that were positive for HLA-B*27:05 or HLA-B*27:02 or negative for
HLA-B*27, and the cells were loaded with peptide overnight and then washed extensively (bottom) or not loaded with peptide (top). Cells were also stimulated
with PMA/ionomycin as positive controls.
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the shape of the peptide’s surface (Fig. 10F and H and 11). The reason behind this
different behavior of the mutant is analogous to the observations made for the
variations at position 100, as discussed above, namely, that the native residue K106 ﬁts
optimally into its MHC binding pocket, whereas the M mutant does not. Thus, K106
forms stable hydrogen bonds with the pocket residues D101 and D98 (Fig. 10E), leading
to an optimal peptide-MHC hydrogen bond network, which is stable throughout the
simulation (Fig. 11A). On the other hand, M106 cannot interact via hydrogen bonding
with the negatively charged D101/D98 (Fig. 10F) and thus moves to the edge of the
binding pocket during the simulation. This leads to large structural rearrangements
within the peptide and a ﬁnal, alternative peptide conformation stabilized by strong
intrapeptide hydrogen bonds between peptide residues R103 and D101 (Fig. 10F and
11B). Due to this alternative conformation, the peptide-TCR interaction surface differs
considerably from that of the original K106 epitope (Fig. 10H versus G), providing a
potential explanation for the missing T cell response to the K106M variant and
consistent with the effect observed for R105K.
Importantly, both variants (R105K and K106M) still show strong MHC binding (Table
4). For R105K, this is directly reﬂected in the MHC-peptide interaction energy (Table 4)
FIG 5 Analysis of T cell responses of HLA-A*02-positive patients to previously described HLA-A*02-
restricted HDV epitopes. PBMCs from 4 HLA-A*02-positive patients with resolved HDV infections were
stimulated with previously described HLA-A*02-restricted HDV epitopes, L-HDAg43–51 (KLEDENPWL) and
L-HDAg26–34 (KLEDLERDL), in a 10-day culture. T cell surface marker staining, as well as ICS, were
performed and analyzed by ﬂow cytometry. The percentage of IFN-/CD8 T cells is indicated in each
diagram. Patient number 4 was not stimulated with L-HDAg26–34 (KLEDLERDL). Negative controls were
treated exactly like the other samples from the respective patients but were not stimulated with peptide
prior to intracellular IFN- staining. Positive controls were stimulated with PMA/ionomycin prior to
intracellular IFN- staining.
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FIG 6 Viral sequence variations within the HLA-B*27-restricted epitopes. Amino acid sequences spanning
the two overlapping HLA-B*27-restricted epitopes, L-HDAg99–108 (RRDHRRRKAL) and L-HDAg103–112
(Continued on next page)
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and is not surprising, as residue 105 is located outside the MHC binding site and thus
does not contribute to MHC-peptide binding. For variant K106M, the calculated inter-
action energy is rather low, which is in contrast to the experimental MHC binding data.
This, however, can be explained by the above-discussed conformational rearrangement
of the peptide due to the mutation, leading to a very strong stabilization of the internal
peptide conformation and thus a very favorable internal energy of the peptide (data
not shown), which comes at the cost of weaker MHC interactions. Interestingly, this
alternative binding mode of a very rigid peptide conformation interacting moderately
with the MHC binding site seems to also lead to very stable bound complexes (the
experimental data are shown in Table 4). Thus, in conclusion, our modeling results
indicate that the missing T cell response to the R105K and K106M variants of the
HLA-B*27:05 epitope L-HDAg99–108 is caused by structural and electrostatic differences
at the TCR interface, which are not directly correlated with the peptides’ HLA-B*27:05
binding strength.
DISCUSSION
In this study, we identiﬁed two overlapping HLA-B*27-restricted CD8 T cell epitopes,
L-HDAg99–108 and L-HDAg103–112, in a conserved region of the only HDV antigen. A
speciﬁc CD8 T cell response to both epitopes was detected in HLA-B*27-positive
patients who were able to resolve their HDV infections. Molecular footprinting using a
collection of HDV isolates from patients with chronic hepatitis delta provided strong
evidence that variations at aa 105 and 106, common to both CD8 T cell epitopes, are
selected. Functional T cell analysis conﬁrmed that aa 105 and 106 variants confer
immune escape on HDV, and in silico structural modeling of the HLA-B*27 epitope
L-HDAg99–108 revealed that both the R105K and the K106M variants dramatically alter
the TCR interface, explaining the immune escape.
Antibodies directed against the HDV nucleoprotein have no neutralizing capacity
FIG 7 Amino acid substitutions at aa 100 of L-HDAg in HDV genotypes 1 to 8. The most frequent viral
protein sequence variations in the region binding to HLA-B*27 within HDV genotype 1 and other HDV
genotypes (2 to 8) are listed.
FIG 6 Legend (Continued)
(RRRKALENKK), were subtracted from HDV isolate sequence analyses. The amino acid sequence align-
ments were sorted by HLA-B*27 haplotype. The ﬁrst six lines show the sequence data from individual
HLA-B*27-positive patients. The rest of the list shows the frequencies of the amino acid variations found
in 98 HLA-B*27-negative patients. Apart from variability at aa 100 and 112 present in both HLA-B*27-
positive and -negative patients, variations within the two epitopes were observed in 6 out of 98
HLA-B*27-negative patients versus 3 out of 6 HLA-B*27-positive patients. Fisher’s exact test was used to
make contingency tables and to calculate the P values for each amino acid–HLA-B*27 correlation. P
values smaller than 0.05 were considered statistically signiﬁcant. Substitutions at residues 105 and 106,
reﬂecting immune escape mutations inside these epitopes, are shaded.
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and are not effective in controlling HDV infection (6). Therefore, T cell response plays
a major role in eliminating HDV, which occurs in about 10 to 20% of HBV carriers who
have been superinfected (26). On the other hand, about 80 to 90% of superinfected
patients are not able to eliminate the virus and develop chronic HDV infection. This may
be due to primary or secondary failure of the T cell response, which in turn may be
caused by T cell exhaustion, by an immune escape of the HDV variants, or simply by an
absence of epitopes to certain HLA alleles within HDV proteins.
HDV has a very short genome of 1.7 kb and only one ORF encoding two isoforms of
one protein (S-HDAg and L-HDAg). The 214-aa L-HDAg comprises all potential epitopes
that may be recognized by T cell responses. In our analysis, the number of peptides
predicted to bind any of the major HLA class I molecules was signiﬁcantly lower than
that of proteins from other viruses, such as hepatitis A virus (HAV), HBV, and HCV
(27–29). The lack of epitopes may be explained by the fact that the HDV protein could
have been derived from a host protein (30) against which T cells are deleted during the
selection of T cells in the thymus. It is notable that we did not detect high-afﬁnity HDV
epitopes binding to HLA alleles other than HLA-B*27, although we used various
approaches. In HLA binding analyses of the predicted peptide epitopes, we observed
only low-afﬁnity binding to, e.g., HLA-A*01:01, HLA-A*02, or HLA-B*07:02, alleles with
high prevalence in Western countries. The low-afﬁnity binding indicates that these
peptides are probably outcompeted by better-binding peptides. A previous study by
Huang et al. described two HLA-A*02 epitopes in Asian patients (12), but we could not
conﬁrm these ﬁndings in 4 HLA-A*02-positive patients with resolved HDV infections in
our study. This may be due to differences in the amino acid sequences of genotype 1
isolates prevalent in East Asia. Moreover, these HLA-A*02:01-restricted HDV epitopes
are located in a highly variable region of L-HDAg that is not conserved in most
European HDV isolates. HDV contains only a few highly conserved regions in its
genome. Among these is the region around the two identiﬁed HLA-B*27 epitopes,
which is conserved throughout all isolates from all genotypes. In fact, our comprehen-
sive analyses of 545 sequences of L-HDAg from all eight HDV genotypes indicated that
the region restricted by HLA-B*27 is conserved within all the genotypes, implying a
possible cross-genotypic HDV-speciﬁc T cell response. This may be a unique feature of
HDV and stands in contrast to earlier ﬁndings made in studies of HCV-speciﬁc T cell
responses, where the protective antiviral effect of HLA-B*27 was shown to be restricted
to HCV genotype 1 and not to any other prevalent genotypes, such as 3a (31). The low
substitution rate in the region may thus be due to viral ﬁtness costs of mutations in the
region.
We demonstrated an HLA-B*27-restricted HDV-speciﬁc CD8 T cell response in some
patients with resolved HDV infections. However, other HDV-infected HLA-B*27-positive
patients fail to clear HDV and develop a persistent infection. We therefore hypothesized
that viral variants emerged that could not be targeted by the relevant virus-speciﬁc CD8
TABLE 3 Deep-sequencing analysis of 11 samples of patients (5 HLA-B*27 positive and 6 HLA-B*27 negative) using UDPS




haplotypes No. of reads
HLA-B*27 positive H09 RQDHRRRKALENKS K111R, 0.8; K112S, 100 14 3,428
H20 RQDHRRRKALENKR 26 3,346
S17 RQDHRRKKALENKK R105K, 100; K111R, 0.8 29 4,244
H36 RQDHRRRKALENKE Q100R, 0.8; K112E, 100 17 3,959
It06 RQDHRRRMALENKK K106M, 100; R105G, 0.3 15 2,341
HLA-B*27 negative H26 RQDHRRRKALENKR 9 3,447
H40 RQDHRRRKALENKR 41 2,422
It04 RQDHRRRKALENKR 22 4,457
It20 RQDHRRRKALENKK K112R, 18.7 46 2,487
S10 RQDHRRRKALENKK K112R, 2 12 3,397
E18 RQDHRRRKALENKK 19 3,277
aThe master sequence corresponding to the epitope region (HDAg codons 99 to 112), with amino acid positions affected by polymorphisms in boldface and
substitutions in relation to the canonical epitope sequence observed in the master sequence underlined.
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T cells. We addressed this possibility by analyzing a multicentric cohort of patients in
which we observed amino acid substitutions in both L-HDAg99–108 and L-HDAg103–112
epitopes abrogating the respective CD8 T cell responses. This sequence variation was
absent in HLA-B*27-negative patients. These ﬁndings were strengthened by deep
sequencing, as we detected minor variations at this location only in the HLA-B*27-
positive patients, in addition to the mutations found by conventional sequencing.
Further longitudinal studies will be of interest to determine whether such minor species
may outgrow the wild-type virus. Classical escape mutations are known as mutations
occurring at anchor positions impairing HLA binding capacity and have been detected
in other viruses, e.g., HBV and HCV. It is noteworthy that none of the escape mutations
described here occur at HLA-B*27 anchor residues. Interestingly, one of the described
variants of the L-HDAg103–112 epitope demonstrated a methionine substitution for
lysine at residue 106 (the fourth residue of the epitope), which was also reported in an
HLA-B*27-restricted HCV epitope, abrogating the T cell response to HCV (31); this may
FIG 8 Functional impacts of amino acid variations in L-HDAg103–112 and L-HDAg99–108 on HDV-speciﬁc
CD8 T cell response. (A) The 10-mer L-HDAg103–112 (RRRKALENKK) or the 9-mer L-HDAg104–112 (RRKALE
NKK) peptide was used to stimulate IFN- responses of CD8 T cells from a donor with resolved HDV
infection (patient C). The functional impacts of K112R, R105K, and K106M amino acid substitutions on the
T cell response were analyzed by ﬂow cytometry using the respective 10-mer (left) and 9-mer (right)
peptides for stimulation. (B) Either highly prevalent L-HDAg99–108 RQDHRRRKAL and RRDHRRRKAL
variants of HDV or rare Q/R100K and Q/R100E variants were used to stimulate IFN- responses of CD8
T cells from a donor with resolved HDV infection (patient B) (2 left columns). The functional impacts of
potential immune escape variants R105K and K106M (indicated in red) on the T cell response were
analyzed by ﬂow cytometry (2 right columns). The negative control was treated exactly like the other
samples from the respective patients but was not stimulated with peptide prior to intracellular IFN-
staining.
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indicate the role of methionine in the T cell interface of HLA-B*27 epitopes, regardless
of their origin. Our study is the ﬁrst report of impairment of the HDV-speciﬁc CD8 T cell
response due to escape mutation, suggesting that genetic diversity of HDV, at least in
part, is driven by immune pressure.
Molecular-modeling studies of the bound complexes of the HDV-speciﬁc epitopes of
L-HDAg99–108 and its potential immune escape variants of HLA-B*27 provide a potential
structural explanation for why variations at the amino acid positions 105 and 106 of the
peptide have a strong impact on TCR binding whereas aa 100 variations do not.
Analysis of the naturally occurring aa 100 variants showed that these mutations do not
FIG 9 Mutation K106M leads to viral escape. PBMCs from patient C 2 and 3 years after HDV clearance (top) were expanded in the
presence of peptide L-HDAg104–112 for 10 days and were then analyzed by intracellular IFN- staining after stimulation with peptide
L-HDAg104–112, as well as the two viral variants K106M () and R105K (Œ) in increasing concentrations. The ELISpot assay was also
performed after stimulation with wild-type or variant peptide in increasing concentrations (bottom). Tests 2 years after HDV clearance
were performed singly due to limitations of cell numbers; tests 3 years after HDV clearance were performed in triplicate (the data are
presented as means  standard deviations). For statistical analysis of responses to variant versus consensus, 2-tailed Student t tests
were performed. A P value of less than 0.05 was considered signiﬁcant. *, P  0.05; ***, P  0.001.
TABLE 4 Experimental and calculated MHC binding and TCR activity data
Peptide Abbreviation MHC binding (%)a T cell activity (%)b Eint (kcal/mol)c
RRDHRRRKAL WT 127.2 13.3 0.59 686.96 15.39
RQDHRRRKAL R100Q 61.0 13.8 0.57 668.75 16.85
REDHRRRKAL R100E 62.6 12.4 0.52 570.54 41.39
RKDHRRRKAL R100K 40.2 5.3 0.50 727.40 3.17
RRDHRRKKALd R105K 92.7 3.7 0.08 678.31 14.93
RRDHRRRMALd K106 M 133.0 2.7 0.18 484.66 24.61
aBinding (standard deviation) of MHC binding of two replicates relative to the positive control (KRWIILGLNK).
bCompare Fig. 10.
cAverage (standard deviation) of the interaction energies (Eint) of two independent MD simulations.
dThe escape mutations are indicated in bold letters.
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FIG 10 Representative structures of L-HDAg99–108 peptide epitopes carrying natural variants R/Q100 or immune
escape variants R105K and K106M bound to HLA-B*27:05. For better visualization, all bound peptide ligands are
oriented from the C to the N terminus (left to right). The HLA-B*27:05 molecule is shown in cartoon representation
in gray, and important residues are shown in atom-type colored licorice representation (cyan carbon atoms). The
peptides are shown in licorice (orange) representation or alternatively as a solvent-accessible surface area colored
according to the electrostatic potential (i.e., blue, positively charged; red, negatively charged; white, neutral areas
of the surface). Hydrogen bonds are shown in magenta. (A and B) Structures of the bound R100 (A) and Q100 (B)
L-HDAg99–108 peptides undergoing alternative binding site interactions; the insets show enlarged views. (C and D)
(Continued on next page)
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affect the TCR binding surface but can signiﬁcantly change the binding pattern with the
HLA-B*27 molecule and thus lead to weaker interactions. This is reasonable, as aa 100
is located in a deep binding pocket of the MHC, four residues away from the two
solvent-exposed arginine residues (R104 and R105) crucial for TCR binding. These
observations are in accordance with our experimental T cell analyses, in which aa 100
variant peptides induced a T cell response comparable to that of wild-type peptides.
In silico analysis also provided an explanation for the importance of the surface-
exposed peptide residues R104 and R105 for TCR binding. This was experimentally
conﬁrmed by the lack of T cell response to the R105K and K106M variants, supporting
the notion that R104 and R105 are crucial for T cell recognition. Our computational
results indicate that the escape mechanism behind the corresponding variants is based
on mutation-induced structural (K106M) and electrostatic (R105K) changes in the
surface region of the bound peptide, which is essential for T cell recognition. Thus, the
structural integrity of the TCR interface seems to be more important than the MHC
binding afﬁnity of the variant. This conclusion is supported by the fact that no
correlation between the experimental or calculated MHC binding properties of the
peptides and their ability to activate T cell responses could be found.
It is important to point out that viral escape may not be the only mechanisms
contributing to virus-speciﬁc CD8 T cell failure during persistent infection. Indeed,
Huang et al. demonstrated HLA*02-restricted HDV-speciﬁc CD8 T cell responses in two
patients with long-term negative HDV RNA (and thus probably recovery from HDV
infection) but were not able to demonstrate HDV-speciﬁc responses in persistently
infected patients, indicating that HDV-speciﬁc CD8 T cells were either not primed in
these patients or had undergone T cell exhaustion and deletion (12). In line with these
results, we also failed to identify HLA-B*27-restricted HDV-speciﬁc CD8 T cells after
antigen-speciﬁc expansion in ﬁve patients with chronic HDV infections (Fig. 3). Even
after performing peptide/MHC multimer bead-based enrichment of HDV-speciﬁc CD8
T cells from ﬁve patients with chronic HDV infections, a technique well established in
our laboratory for enrichment of low-frequency populations for virus-speciﬁc CD8 T
cells (32, 33), we were not able to detect HDV-speciﬁc CD8 T cells in chronically
infected patients (Fig. 13). These data support the hypothesis that HDV-speciﬁc CD8
T cells undergo ﬁnal exhaustion and deletion in patients with chronic HBV-HDV
coinfections. In addition, sequestration of HDV-speciﬁc CD8 T cells in the liver may be
FIG 11 Inter- and intramolecular hydrogen bonds of the L-HDAg99–108 epitope (A) and the K106M variant
of the L-HDAg99–108 epitope (B) monitored over the simulation time. A vertical black line indicates that
at least one hydrogen bond is formed at a speciﬁc time frame during the simulation between the
functional groups of the two amino acid residues shown on the y axis. The percentage of simulation time
during which a hydrogen bond exists is shown on the right. The L-HDAg99–108 epitope and K106M variant
amino acid residues are depicted in orange, and MHC binding pocket amino acid residues are shown in
cyan.
FIG 10 Legend (Continued)
Structures of the bound wild-type L-HDAg99–108 peptide (C) and its variant R105K (D). The residues R105 and R104
are boxed in yellow. (E to H) Structures of the bound wild-type (E and G) and variant K106M (F and H) peptides
that lose their interaction with one of the HLA-B*27:05 -helices. The insets provide enlarged views of the binding
site interactions. (G and H) Structural representations of the MHC binding site, with the bound peptide shown as
a surface representation.
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an alternate explanation for their absence in peripheral blood. In contrast, using this
technique, HDV-speciﬁc CD8 T cells were readily detectable in a patient with cleared
HDV infection but persistent low-level HBV viremia. These HDV-speciﬁc CD8 T cells
were antigen experienced (not naive, as indicated by CCR7 and CD45RA costaining) and
displayed high expression of PD1 but varying expression levels of CD127.
Overall, our results indicate that the number of potential epitopes to the frequent
HLA alleles in the 214 aa of the single protein of HDV is very low; only two HLA-B*27-
restricted epitopes have been deﬁned so far, whereas for all major HLA alleles present
in the European population, no epitope has so far been identiﬁed. The low number of
epitopes and T cell failure resulting from immune escape may contribute to the high
chronicity rate in HDV infection, in addition to the immunoinhibitory environment
established by persistent HBV infection that persistent HDV infection is tied to. The
hypothesis that HLA-B*27 maybe a protective allele against HDV, as shown in other
infections, like HIV and HCV, has to be veriﬁed by initiation of a prospective study in a
larger cohort with patients who are HLA-B*27 positive or negative. These data also
imply that the development of effective antiviral approaches, e.g., immunotherapy,
against HDV will be a challenging task.
MATERIALS AND METHODS
Patient cohorts and samples. Chronically HDV-infected patients (n  104; anti-HDV HDV RNA/)
were recruited from 8 different medical centers located in Germany (Essen, Freiburg, Hannover, and
Munich), Spain, Italy, and Iran. HLA backgrounds, as well as L-HDAg sequences, were determined.
HLA class I typing was performed with a Luminex PCR sequence-speciﬁc oligonucleotide (PCR-SSO)
probe, using LabType SSO kits (One Lambda, Canoga Park, CA, USA) (20), from genomic DNA extracted
from blood samples using a column puriﬁcation kit (Qiagen, Hilden, Germany). Two-digit HLA typing and,
in selected patients, high-resolution typing were done to deﬁne four-digit HLA types or subgroups.
HDV phylogenetic analysis and epitope prediction. Total RNA was extracted from the patient’s
serum samples and was reverse transcribed into cDNA by reverse transcriptase from Moloney murine
leukemia virus (Promega, Madison, WI, USA) at 37°C for 1 h using HDV-speciﬁc primer 771R (Table 5). In
order to obtain sequences of the L-HDAg-encoding region, cDNA products from the reverse transcription
step were ampliﬁed by Pfu DNA polymerases (Promega, USA) in a two-step nested PCR. The PCR steps
using HDV-speciﬁc primers 891-F, 339-R, 912-F, and 1674-R were performed under the following thermal
proﬁle: 94°C for 10 min; 35 cycles of 94°C for 30 s, 54°C for 45 s, and 72°C for 90 s; and then an elongation
step at 72°C for 7 min. Finally, the PCR products were puriﬁed via QIAquick gel extraction (Qiagen) and
directly sequenced on an ABI 3730xl DNA analyzer using internal primers 912-F and 1674-R.
HDV sequences from this study and NCBI GenBank were aligned using ClustalX2 software (34). A
maximum-likelihood phylogenetic tree was constructed under the Tamura-Nei substitution model using
MEGA software v6 (35). The reliability of the pairwise comparison and phylogenetic tree analysis was
FIG 12 Representative structures of L-HDAg99–108 peptide epitopes carrying the natural variants K/E100 bound to HLA-B*27:05. For better
visualization, all the bound peptide ligands are oriented from the C to the N terminus (left to right). The MHC molecule is shown in cartoon
representation in gray, and important residues are shown in atom-type colored licorice representation (cyan carbon atoms). The peptides
are shown in licorice (orange) representation. Hydrogen bonds are shown in magenta. The insets provide enlarged views of the binding
site interactions. (A) Structure of the bound K100 peptide variant. (B) Structure of the bound E100 peptide variant.
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assessed by 1,000-replicate bootstrapping. The genotypes of HDV strains were determined by compar-
ison to full-length L-HDAg reference sequences from GenBank.
Next-generation sequencing was performed in 11 selected samples to identify variations at a
detection level of 0.1% and to pin down variations in the region ﬂanked by nucleotide positions 956 to
1,360 by ultradeep pyrosequencing (UDPS) (primer sequences are listed in Table 5). The amplicons had
a length of 515 bp and were isolated from 0.9% agarose gels with the QIAquick extraction kit (QIAquick
spin handbook; Qiagen, Hilden, Germany) and quantiﬁed using Quan-iTPicogreens DNA reagent (Invit-
rogen). UDPS was performed with the 454/GS-Junior platform (Roche, Branford, CT, USA) using titanium
chemistry (GS-Junior titanium sequencing kit). The FASTA ﬁle from the GS-Junior was demultiplexed and
ﬁltered as recently described (36). The speciﬁc region analyzed by UDPS (after discarding primer
sequences) covered nucleotides (nt) 977 to 1338 of the HDV genome (362 nt were analyzed). All the
sequences were submitted as a new BioProject to GenBank. FASTA reads were ﬁltered and analyzed as
recently described (37).
Two hundred L-HDAg sequences of HDV genotype 1 from GenBank were applied for epitope
prediction using the IEDB (http://www.iedb.org) and the SYFPEITHI database (http://www.syfpeithi.de)
algorithms (38–40) to predict potential binders to the most common alleles in Europeans (41): HLA-A*02,
-A*01, -A*03, -A*11, -A*24, -B*35, -B*51, -B*07, -B*18, -B*08, and -B*27.
Analysis of HLA binding capabilities of candidate peptides. The binding afﬁnities of the predicted
epitopes were analyzed with the UV-mediated peptide exchange assay using PeliChange p*HLA-A*01:01,
FIG 13 Ex vivo peptide/tetramer bead-based enrichment of L-HDAg104-112-speciﬁc CD8 T cells in
patients with resolved versus chronic HDV infections. (A) L-HDAg104-112 peptide/HLA-B*27:05 tetramer
bead-based ex vivo enrichment of HDV-speciﬁc CD8 T cells was performed for ﬁve patients with chronic
HBV/HDV coinfections, as well as one patient with chronic HBV infection and resolved HDV infection (32).
Using this extremely sensitive method, we were able to detect HDV-speciﬁc CD8 T cells from a patient
with chronic HBV infection and resolved HDV infection. In contrast, we were not able to enrich
HDV-speciﬁc CD8 T cells from the ﬁve patients with chronic HBV-HDV coinfections. The autologous
sequences are also displayed (ND, viral sequencing not done due to low viral load). (B) Ex vivo-enriched
HDV-speciﬁc CD8 T cells from the patient with chronic HBV infection and resolved HDV infection were
further analyzed for expression of PD1 and CD127. Naive CD8 T cells were excluded by costaining for
CCR7 and CD45RA.
TABLE 5 Primers used in L-HDAg ampliﬁcation for direct and deep sequencing






M13 HDV 956a 5=-GTTGTAAAACGACGGCCAGTTCACTGGGGTCGACAACTCTG-3=
M13 HDV 1360a 5=-CACAGGAAACAGCTATGACCGTAGACTCCGGACCTAGGAAGA-3=
OligoAMIDM13fwb 5=-CGTATCGCCTCCCTCGCGCCATCAGMIDGTTGTAAAACGACGGCCAGT-3=
OligoBMIDM13rvb 5=-CTATGCGCCTTGCCAGCCCGCTCAGMIDCACAGGAAACAGCTATGACC-3=
aM13 HDV 956 and M13 HDV 1360 primers consist of M13 fagus universal tail at the 5´ ends followed by HDV-speciﬁc sequences (underlined).
bSpeciﬁc oligonucleotides for UDPS are indicated in bold followed by multiplex identiﬁers (MID) and the M13 fagus universal tails.
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-A*02:01, -A*03:01, -A*24:02, -B*07:02, and -B*27:05 kits (Sanquin, Amsterdam, The Netherlands) as
described previously (27, 42). Brieﬂy, peptide exchange reactions were performed by exposure for 30 min
of conditional pHLA complexes (0.53 M) to long-wavelength UV using a 366-nm UV lamp (Camag,
Muttenz, Switzerland) in the presence or absence of the indicated peptide (50 M). Subsequently, the
peptide exchange efﬁciency was analyzed using an HLA class I enzyme-linked immunosorbent assay
(ELISA), which detects beta-2 microglobulin of peptide-stabilized HLA class I complexes in a properly
diluted exchange reaction mixture. To this end, streptavidin (2 g/ml) was bound onto polystyrene
microtiter wells (Nunc MaxiSorp). After washing and blocking, HLA complex present in exchange reaction
mixtures or controls was captured by the streptavidin on the microtiter plate via its biotinylated heavy
chain (with incubation for 1 h at 37°C). Nonbound material was removed by washing. Subsequently,
horseradish peroxidase (HRP)-conjugated antibody to human beta-2-microglobulin (0.6 g/ml) was
added (with incubation for 1 h at 37°C). After removal of nonbound HRP conjugate by washing, an ABTS
[2,2=-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt] substrate solution was added to
the wells. The reaction was stopped after 8 min (incubation at room temperature) by the addition of a
stop solution and read in an ELISA reader at 414 nm. Every peptide was independently exchanged twice.
Every exchange mixture was measured in duplicate in the HLA class I ELISA. The absorbances of all the
peptides were normalized to the absorbance of a known HLA allele-speciﬁc ligand with high afﬁnity for
each corresponding allele (representing 100%). Negative controls included an HLA allele-speciﬁc non-
binder and UV irradiation of the conditional HLA class I complex in the absence of a rescue peptide.
Polyclonal antigen-speciﬁc expansion of T cells. Patient PBMCs were obtained by standard Ficoll
density centrifugation (Biocoll; Biochrom, Germany). Freshly isolated PBMCs (2  106) were cultured in
1 ml complete medium (RPMI 1640 medium supplemented with 10% fetal calf serum, 100 U/ml penicillin,
100 g/ml streptomycin) containing anti-CD28 antibody (0.5 g/ml; BD Biosciences). The cells were
stimulated with 31 synthetic overlapping 16-mer peptides (EMC Microcollections, Tübingen, Germany;
ﬁnal concentration, 10 g/ml per peptide) corresponding to the complete sequence of L-HDAg divided
into 8 pools (pools A to H) or individual 10-mer or 11-mer peptides. On day 2, 1 ml complete medium
and interleukin-2 (10 U/ml; Roche, Basel, Switzerland) were added. On days 10 and 12, the cells were
tested for IFN- secretion by intracellular-cytokine staining after restimulation with the peptide pools
(day 10) or individual peptides from the positive pool (day 12) as described previously (43). Prior to
staining, the cells were cultured for 5 h in the presence of peptides (10 g/ml) and 5 g/ml brefeldin A
(Sigma-Aldrich, St. Louis, MO, USA). The cells were stained using allophycocyanin (APC)-conjugated
anti-CD8 and phycoerythrin (PE)-conjugated anti-CD4 at 4°C for 15 min. After permeabilization, the cells
were stained with ﬂuorescein isothiocyanate (FITC)-conjugated anti-IFN- monoclonal antibody (MAb)
(all reagents were from BD Biosciences) and analyzed by ﬂow cytometry on a FACSCalibur instrument (BD
Biosciences). Dead cells were stained using Viaprobe reagent (BD Biosciences) and excluded from
analyses. Data ﬁles were analyzed with FlowJo 7.6.5 software (Tree Star, Ashland, OR).
Computational modeling of HLA-B*27 binding. To investigate the binding properties of selected
L-HDAg-derived peptides to HLA-B*27:05 on the structural level, in silico modeling studies were per-
formed. The investigated peptide–HLA-B*27:05 complexes were modeled on the basis of the crystal
structure of the peptide–HLA-B*27:05 complex with Protein Data Bank (PDB) accession no. 4G9D (44).
Only the 1 and 2 subdomains of the HLA-B*27:05 protein (residues 25 to 206), forming the peptide-
binding cleft, were considered during modeling. The peptide sequence was mutated using the IRECS
algorithm (45, 46). To allow the HLA-B*27:05 peptide-binding cleft to adapt to the mutated peptide,
HLA-B*27:05 side chains were subsequently also remodeled with IRECS. The modeled peptide–HLA-
B*27:05 complexes were energy minimized in a neutralized, rectangular box of TIP3P (47) water
molecules with a minimum solute distance to the box boundary of 12 Å. The general system setup and
the simulations were conducted with AmberTools 14 and the Amber 14 software package (48). The
Amber ff99SBILDN force ﬁeld (49) was chosen. MD simulations were performed using a time step of 1 fs.
The SHAKE algorithm (50) was applied to all bonds involving hydrogen atoms. Long-range electrostatic
interactions were computed using the particle mesh Ewald (PME) method (using the molecular dynamics
program pmemd.cuda_SPFP) (51). A cutoff of 14 Å was used for the computation of nonbonded
interactions. Temperature and pressure were controlled by applying the Berendsen thermostat and barostat
with default settings (52). The systems were stepwise heated to 300 K while gradually decreasing solute atom
restraints, using the NVT (constant number of particles N, constant volume V, and constant temperature T)
ensemble. Afterward, NPT (constant number of particles N, constant pressure P, and constant temperature
T)-based molecular dynamics simulations were performed for 20 ns for each system.
Trajectory processing and analysis were done with CPPTRAJ (53). MD frames for analysis were
extracted every 20 ps from the last 5 ns of the simulations. Representative conformations were obtained
by conformational clustering using the average linkage method with a cutoff of 2 Å, and hydrogen bonds
and peptide–HLA-B*27:05 interaction energies were calculated by applying the default settings of
CPPTRAJ. Electrostatic potentials were calculated using the PDB2PQR server (version 2.1.1) and APBS
(version 1.2.1) (54, 55), keeping the default settings. Mapping of electrostatic potentials to the solvent-
accessible surface areas of the peptide ligands was performed with VMD (version 1.9) (56). Figures
showing peptide–HLA-B*27:05 complexes were also generated with VMD (version 1.9).
Study approval. Local ethics committees approved this study according to the 1975 Declaration of
Helsinki guidelines. The main approaches for analyzing the HDV-speciﬁc T cell immune responses in
HDV-infected patients were approved by the Ethics Committee of the Faculty of Medicine of Duisburg-
Essen University (10-4472). The protocol for isolating and analyzing genomic DNA (genome-wide
association study) was also approved by the Ethics Committee of the Medical School of Hannover (OE
9515/no. 3388 and no. 5292M). The Ethics Committee of the Albert-Ludwigs-Universität Freiburg, no.
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369-15, approved the protocol for investigation of viral escape from the dominant virus-speciﬁc CD8 T
cell response in HBV monoinfection and HBV-hepatitis delta virus coinfection and strategies to restore
the antiviral CD8 T cell response. All the patients who participated in the study were interviewed and
informed about the concept of the study and possible side effects before they agreed to participate by
giving written informed consent.
Accession number(s). The newly determined sequences are available under GenBank accession
numbers MF175257 to MF175360, BioProject accession number PRJNA434630, and SRA accession
number SRP133994.
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